BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 21865091)

  • 1. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.
    Ip PP; Cheung AN
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):691-704. PubMed ID: 21865091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
    Ip PP; Tse KY; Tam KF
    Adv Anat Pathol; 2010 Mar; 17(2):91-112. PubMed ID: 20179432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects.
    Waldmann J; Stachs A; Terpe H; Stropahl G; Makovitzky J
    Anticancer Res; 2005; 25(3A):1559-65. PubMed ID: 16033061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic considerations of uterine smooth muscle tumors.
    Prayson RA; Hart WR
    Obstet Gynecol Clin North Am; 1995 Dec; 22(4):637-57. PubMed ID: 8786875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic study of 51 cases.
    Lee TK; Miyamoto H; Osunkoya AO; Guo CC; Weiss SW; Epstein JI
    Am J Surg Pathol; 2010 Apr; 34(4):502-9. PubMed ID: 20154594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine smooth muscle tumors of uncertain malignant potential and atypical leiomyoma: a morphological study of these grey zones with clinical correlation.
    Deodhar KK; Goyal P; Rekhi B; Menon S; Maheshwari A; Kerkar R; Tongaonkar HB
    Indian J Pathol Microbiol; 2011; 54(4):706-11. PubMed ID: 22234095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inguinal smooth muscle tumors in women-a dichotomous group consisting of Müllerian-type leiomyomas and soft tissue leiomyosarcomas: an analysis of 55 cases.
    Patil DT; Laskin WB; Fetsch JF; Miettinen M
    Am J Surg Pathol; 2011 Mar; 35(3):315-24. PubMed ID: 21297441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of biological potential of smooth muscle tumours.
    Miettinen M; Fetsch JF
    Histopathology; 2006 Jan; 48(1):97-105. PubMed ID: 16359541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
    Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
    Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
    Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
    Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
    Mittal K; Demopoulos RI
    Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors.
    Fadare O; Liang SX
    Ann Diagn Pathol; 2008 Dec; 12(6):401-5. PubMed ID: 18995203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions.
    Quade BJ
    Curr Opin Obstet Gynecol; 1995 Feb; 7(1):35-42. PubMed ID: 7742513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uterine smooth-muscle tumors of uncertain malignant potential.
    Peters WA; Howard DR; Andersen WA; Figge DC
    Obstet Gynecol; 1994 Jun; 83(6):1015-20. PubMed ID: 8190416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings.
    Tanaka YO; Nishida M; Tsunoda H; Okamoto Y; Yoshikawa H
    J Magn Reson Imaging; 2004 Dec; 20(6):998-1007. PubMed ID: 15558559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fascin expression in uterine smooth muscle tumors.
    Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
    Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
    Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
    Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myxoid leiomyosarcoma of the uterus.
    Burch DM; Tavassoli FA
    Histopathology; 2011 Dec; 59(6):1144-55. PubMed ID: 22175894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.